# US 2026/0232782 A1 · Hemolysin antigens and vaccine embodiments for bacterial infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232782 A1
- Document ID: US20260232782A1
- Status: Published application
- Kind: A1
- Application number: 19/156,551
- Filed: 2024-02-16
- Published: 2026-08-13
- Earliest claimed: 2023-02-16
- Assignees: Baylor College of Medicine
- Applicants: Baylor College of Medicine
- Inventors: Yikun Xing; Anthony Maresso; Justin R. Clark
- Web page: https://patentgrep.com/patent/US20260232782A1

## CPC

- A61K 39/0258: {Escherichia}
- C07K 14/245: Escherichia (G)
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/575: {humoral response}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Embodiments of the disclosure include methods of treating, preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of an infection (including pathogenic) in an individual infected with a bacteria from the Gammaproteobacteria Class. In specific embodiments, the methods comprise the step of administering to the individual an effective amount of an immunogenic composition comprising a non-acylated/inactive form alphahemolysin (HlyA) and/or a non-acylated/inactive form, or functional fragment(s) of either. In specific embodiments, the individual is also provided a composition comprising SinH or a functional fragment thereof.

## Claims

### Claim 1

A method of treating, preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of an infection in an individual of a bacteria from the Gammaproteobacteria Class, comprising the step of administering to the individual an effective amount of a composition comprising a non-acylated/inactive form alpha-hemolysin (HlyA) and/or a non-acylated/inactive form or functional fragment thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inactive HlyA is from the absence of the catalytic acylation enzyme, HlyC.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the inactive HlyA is non-acylated.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the inactive HlyA is not capable of inducing pore formation.

### Claim 5 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the inactive HlyA is not capable of inducing calcium influx.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the bacteria is in the Enterobacterales Order.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the bacteria is in the Enterobacteriaceae family.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the bacteria is in the Genus Escherichia, Vibrio Shigella, Salmonella, Yersinia, Enterobacter, Morganella, or Citerobacter.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the bacteria is Escherichia coli, Vibrio parahaemolyticus, Shigella sonnei, Shigella flexneri, Shigella boydii, Shigella dysenteriae, Salmonella bongori, Salmonella enterica, Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Enterobacter huaxiensis, Enterobacter chuandaensis, Enterobacter aerogenes, Enterobacter amnigenus, Enterobacter arachidis, Enterobacter asburiae, Enterobacter carcinogenus, Enterobacter cloacae, Enterobacter cowanii, Enterobacter dissolvans, Enterobacter gergoviae, Enterobacter helveticus, Enterobacter hormaechei, Enterobacter kobei, Enterobacter ludwigii, Enterobacter mori, Enterobacter nimipressuralis, Enterobacter oryzae, Enterobacter pulveris, Enterobacter pyrinus, Enterobacter radicincitans, Enterobacter soli, Enterobacter taylorae, Enterobacter turicensis, Morganella morganii, Citerobacter freundii, Citerobacter koseri, Citerobacter amalonaticus, Citerobacter farmeri, Citerobacter youngae, Citerobacter braakii, Citerobacter werkmanii, Citerobacter sedlakii, Citerobacter rodentium, Citerobacter gillenii, or Citerobacter murliniae.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the HlyA is from a bacteria member of the Enterobacterales Order.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the HlyA is from a bacteria member of the Enterobacteriaceae family.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the HlyA is from a bacteria member of the Genus Escherichia, Vibrio Shigella, Salmonella, Yersinia, Enterobacter, Morganella, or Citerobacter.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the HlyA is from Escherichia coli, Vibrio parahaemolyticus, Shigella sonnei, Shigella flexneri, Shigella boydii, Shigella dysenteriae, Salmonella bongori, Salmonella enterica, Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Enterobacter huaxiensis, Enterobacter chuandaensis, Enterobacter aerogenes, Enterobacter amnigenus, Enterobacter arachidis, Enterobacter asburiae, Enterobacter carcinogenus, Enterobacter cloacae, Enterobacter cowanii, Enterobacter dissolvans, Enterobacter gergoviae, Enterobacter helveticus, Enterobacter hormaechei, Enterobacter kobei, Enterobacter ludwigii, Enterobacter mori, Enterobacter nimipressuralis, Enterobacter oryzae, Enterobacter pulveris, Enterobacter pyrinus, Enterobacter radicincitans, Enterobacter soli, Enterobacter taylorae, Enterobacter turicensis, Morganella morganii, Citerobacter freundii, Citerobacter koseri, Citerobacter amalonaticus, Citerobacter farmeri, Citerobacter youngae, Citerobacter braakii, Citerobacter werkmanii, Citerobacter sedlakii, Citerobacter rodentium, Citerobacter gillenii, or Citerobacter murliniae.

### Claim 14

A method of vaccinating an individual for a pathogenic infection of a bacteria from the Gammaproteobacteria Class, comprising the step of administering to the individual an effective amount of a composition comprising a non-acylated/inactive form of alpha-hemolysin (HlyA) and/or a non-acylated/inactive form or functional fragment thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the bacteria is in the Enterobacterales Order.

### Claim 16 (depends on 14, 15)

The method of claim 14 or 15, wherein the bacteria is in the Enterobacteriaceae family.

### Claim 17 (depends on 14, 15, 16)

The method of any one of claims 14-16, wherein the bacteria is in the Genus Escherichia, Vibrio Shigella, Salmonella, Yersinia, Enterobacter, Morganella, or Citerobacter.

### Claim 18 (depends on 14, 15, 16, 17)

The method of any one of claims 14-17, wherein the bacteria is Escherichia coli, Vibrio parahaemolyticus, Shigella sonnei, Shigella flexneri, Shigella boydii, Shigella dysenteriae, Salmonella bongori, Salmonella enterica, Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Enterobacter huaxiensis, Enterobacter chuandaensis, Enterobacter aerogenes, Enterobacter amnigenus, Enterobacter arachidis, Enterobacter asburiae, Enterobacter carcinogenus, Enterobacter cloacae, Enterobacter cowanii, Enterobacter dissolvans, Enterobacter gergoviae, Enterobacter helveticus, Enterobacter hormaechei, Enterobacter kobei, Enterobacter ludwigii, Enterobacter mori, Enterobacter nimipressuralis, Enterobacter oryzae, Enterobacter pulveris, Enterobacter pyrinus, Enterobacter radicincitans, Enterobacter soli, Enterobacter taylorae, Enterobacter turicensis, Morganella morganii, Citerobacter freundii, Citerobacter koseri, Citerobacter amalonaticus, Citerobacter farmeri, Citerobacter youngae, Citerobacter braakii, Citerobacter werkmanii, Citerobacter sedlakii, Citerobacter rodentium, Citerobacter gillenii, or Citerobacter murliniae.

### Claim 19 (depends on 14, 15, 16, 17, 18)

The method of any one of claims 14-18, wherein the HlyA is from a bacteria member of the Enterobacterales Order.

### Claim 20 (depends on 14, 15, 16, 17, 18, 19)

The method of any one of claims 14-19, wherein the HlyA is from a bacteria member of the Enterobacteriaceae family.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 14-20, wherein the HlyA is from a bacteria member of the Genus Escherichia, Vibrio Shigella, Salmonella, Yersinia, Enterobacter, Morganella, or Citerobacter.

### Claim 22 (depends on 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 14-21, wherein the Hly A is from Escherichia coli, Vibrio parahaemolyticus, Shigella sonnei, Shigella flexneri, Shigella boydii, Shigella dysenteriae, Salmonella bongori, Salmonella enterica, Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Enterobacter huaxiensis, Enterobacter chuandaensis, Enterobacter aerogenes, Enterobacter amnigenus, Enterobacter arachidis, Enterobacter asburiae, Enterobacter carcinogenus, Enterobacter cloacae, Enterobacter cowanii, Enterobacter dissolvans, Enterobacter gergoviae, Enterobacter helveticus, Enterobacter hormaechei, Enterobacter kobei, Enterobacter ludwigii, Enterobacter mori, Enterobacter nimipressuralis, Enterobacter oryzae, Enterobacter pulveris, Enterobacter pyrinus, Enterobacter radicincitans, Enterobacter soli, Enterobacter taylorae, Enterobacter turicensis, Morganella morganii, Citerobacter freundii, Citerobacter koseri, Citerobacter amalonaticus, Citerobacter farmeri, Citerobacter youngae, Citerobacter braakii, Citerobacter werkmanii, Citerobacter sedlakii, Citerobacter rodentium, Citerobacter gillenii, or Citerobacter murliniae.

### Claim 23

A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of the systemic spread of bacteria to one or more major organ systems of an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof or a functional fragment thereof.

### Claim 24

A method of reducing the bacterial burden of an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof

### Claim 25

A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of bacteremia in an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof.

### Claim 26

A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of a urinary tract infection in an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof.

### Claim 27

A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of colonization of bacteria from the Gammaproteobacteria Class in an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof.

### Claim 28

A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of sepsis in an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof.

### Claim 29

The method of any one of the preceding claims, further comprising the step of administering to the individual an effective amount of a composition comprising SinH or a functional fragment thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the composition comprising the inactive HlyA or a functional fragment thereof is provided to the individual in the same formulation as the composition comprising the SinH or a functional fragment thereof.

### Claim 31 (depends on 29)

The method of claim 29, wherein the composition comprising the inactive HlyA or a functional fragment thereof is provided to the individual in a different formulation as the composition comprising the SinH or a functional fragment thereof.

### Claim 32 (depends on 31)

The method of claim 31, wherein the composition comprising the inactive HlyA or a functional fragment thereof is administered to the individual prior to administering the composition comprising the SinH or a functional fragment thereof.

### Claim 33 (depends on 31)

The method of claim 31, wherein the composition comprising the inactive HlyA or a functional fragment thereof is administered to the individual subsequent to administering the composition comprising the SinH or a functional fragment thereof.

### Claim 34 (depends on 31)

The method of claim 31, wherein the composition comprising the inactive HlyA or a functional fragment thereof is administered to the individual at the same time as administering the composition comprising the SinH or a functional fragment thereof.

### Claim 35

The method of any one of the preceding claims, wherein the bacteria is drug-resistant.

### Claim 36

The method of any one of the preceding claims, wherein the bacteria is multidrug-resistant.

### Claim 37

The method of any one of the preceding claims, wherein the bacteria is E. coli and the E. coli is ST73, ST95, or ST131.

### Claim 38

The method of any one of the preceding claims, wherein the bacteria is extraintestinal pathogenic Escherichia coli (ExPEC).

### Claim 39

The method of any one of the preceding claims, wherein the functional fragment of SinH comprises extracellular domain 1, domain 2, and/or domain 3.

### Claim 40

The method of any one of the preceding claims, wherein the infection is local.

### Claim 41

The method of any one of the preceding claims, wherein the infection is systemic.

### Claim 42

The method of any one of the preceding claims, wherein the individual is immunocompromised.

### Claim 43

The method of any one of the preceding claims, wherein the individual is an infant, child, adolescent, or adult.

### Claim 44

The method of any one of the preceding claims, wherein the individual is at least 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90, 95, or 100 or more years of age.

### Claim 45

The method of any one of the preceding claims, wherein the individual has recurrent urinary tract infections.

### Claim 46

The method of any one of the preceding claims, wherein the individual is in a medical facility or has been or will be in a medical facility within 1, 2, 3, 4, 5, 6, or 7 days, or within 1, 2, 3, 4 week, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years.

### Claim 47 (depends on 46)

The method of claim 46, wherein the medical facility is a hospital or nursing home or skilled nursing home or long-term care facility.

### Claim 48

The method of any one of the preceding claims, wherein the individual lacks a pathogenic E. coli infection.

### Claim 49

The method of any one of the preceding claims, wherein the individual has a pathogenic E. coli infection.

### Claim 50

The method of any one of the preceding claims, wherein the administering step occurs once.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 1-50, wherein the administering step occurs more than once.

### Claim 52 (depends on 51)

The method of claim 51, wherein the duration between successive administrations is, or is at least, or is no more than within 1, 2, 3, 4, 5, 6, or 7 days, or within 1, 2, 3, 4 week, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years.

### Claim 53

The method of any one of the preceding claims, wherein the composition comprises an adjuvant.

### Claim 54

The method of any one of the preceding claims, wherein the SinH functional fragment is part of a conjugate, wherein the inactive HlyA functional fragment is part of a conjugate, or both.

### Claim 55

A composition comprising a non-acylated/inactive form alpha-hemolysin (HlyA) and/or a non-acylated/inactive form or functional fragment thereof in a pharmaceutically acceptable excipient.

### Claim 56 (depends on 55)

The composition of claim 55, further comprising an antibiotic, SinH, the extracellular domain 1 of SinH, the extracellular domain 2 of SinH, the extracellular domain 3 of SinH, one or more O-antigens, one or more K-antigens, and/or FimH (Type 1 fimbriae protein).

### Claim 57 (depends on 55, 56)

A kit comprising the composition of claim 55 or 56, housed in a suitable container.
